- All
- 2026-06-11 [Thursday]
- 2026-06-12 [Friday]
- 2026-06-13 [Saturday]
- 2026-06-14 [Sunday]
- All
- A1-A (102-107)
- A1-A101
- A1-A102
- A1-A103
- A1-A104
- A1-A (105-107)
- A1-A108
- A1-A109
- A1-A110
- A2-A207
- A2-A208
- A1-A213
- A1-A214
- A1-A215
- B1 Hall (Poster Area)
- B1 Hall (Exhibition Area)
2026-06-11 (Thursday)
A1-A108
| NO. | Time | Presentation Topic | Speaker | Affiliation / Organization |
|---|---|---|---|---|
| 1 | 14:00-14:05 |
Opening |
Gao-Jun Teng | Zhongda Hospital, Southeast University, China |
| 2 | 14:05-14:13 |
MRI-based Radiomics Model for Predicting Prognosis in HCC Patients Receiving TACE Combined with Atezolizumab and Bevacizumab |
Qing-Quan Zu | Jiangsu Province Hospital, China |
| 3 | 14:13-14:21 |
Precision TACE Combined with Systemic Therapy for Advanced HCC: A Comprehensive Case Analysis and Future Directions |
Mao Yang | Tianjin Cancer Hospital Airport Hospital, China |
| 4 | 14:21-14:29 |
precision TACE Combined with Systemic Therapy for Advanced HCC |
Hao-Chen Wang | Beijing Friendship Hospital, Capital Medical University, China |
| 5 | 14:29-14:37 |
Low-Dose TKI Optimizes TACE-Based Combination Therapy by Targeting Microvasculature and Promoting HEV-Mediated Immune Remodeling in Hepatocellular Carcinoma |
Xue Han | Sun Yat-sen University Cancer Center, China |
| 6 | 14:37-14:45 |
Atezolizumab plus bevacizumab reduce peritoneal metastasis risk for patients with ruptured HCC receiving TACE/TAE : a multicenter retrospective study |
Fu-An Wang | Jiangsu Subei People's Hospital, China |
| 7 | 14:45-14:53 |
Curative Conversion Resection Following Sequential HAIC, Atezolizumab+Bevacizumab, and Y-90 SIRT for Unresectable Hepatocellular Carcinoma with Hepatic Arterioportal Fistula: A Case Report |
Tuo-Xuan Jin | The First Affiliated Hospital of China Medical University, China |
| 8 | 14:53-15:05 |
Panel Discussion |
Jin Woo Choi | Seoul National University Hospital, ROK(Republic of Korea) |
| NO. | Time | Presentation Topic | Speaker | Affiliation / Organization |
|---|---|---|---|---|
| 1 | 15:05-15:13 |
Adjuvant Hyperbaric Oxygen Therapy with Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma: A Pilot Study on Efficacy and Safety |
Rui An | Xijing Hospital, The Fourth Military Medical University, China |
| 2 | 15:13-15:21 |
Clinical study of TACE/HAIC combined with intra-arterial infusion of atezolizumab + bevacizumab for the treatment of medium-to-advanced HCC |
Song-Nan Zhang | Yanbian University Hospital, China |
| 3 | 15:21-15:29 |
Application of Blood Supply–Based TACE Sequential HAIC Combined with T+A in Conversion Therapy for Intermediate-Advanced HCC: A Multicenter Retrospective Study |
Jin-Long Yan | Second Affiliated Hospital of Nanchang University, China |
| 4 | 15:29-15:37 |
Percutaneous Interventional Retrieval of a Dislodged Intrahepatic TIPS Stent: Technical Innovation and Clinical Experience from a Complex Case |
Lei Li | First Hospital Affiliated to Lanzhou University, China |
| 5 | 15:37-15:45 |
Locoregional Therapy Beyond TACE+systemic therapy |
Li-Yun Zheng | Lishui Hospital of Zhejiang University, China |
| 6 | 15:45-15:53 |
SBRT Followed by Sintilimab and Ipilimumab-N01 Combined with HAIC for Advanced Hepatocellular Carcinoma After Failure of Prior Targeted Therapy and Immunotherapy: A Trial in Progress |
Hui Zeng | Zhejiang Provincial Cancer Hospital, China |
| 7 | 15:53-16:01 |
Yttrium-90 SIRT plus atezolizumab/bevacizumab in unresectable huge HCC (>10 cm):A multicenter retrospective study |
Hui Zhang | The First Affiliated Hospital of the Army Medical University, China |
| 8 | 16:01-16:13 |
Panel Discussion |
Hyo-Cheol Kim | Seoul National University Hospital, ROK(Republic of Korea) |
| NO. | Time | Presentation Topic | Speaker | Affiliation / Organization |
|---|---|---|---|---|
| 1 | 16:13-16:21 |
Efficacy of QL1706 Combined with Intra-Arterial Intervention and Bevacizumab in Refractory Hepatocellular Carcinoma After Targeted and Immunotherapy |
Tian-Qi Zhang | Sun Yat-sen University Cancer Center, China |
| 2 | 16:21-16:29 |
TACE Combined with HAIC, TKIs, and ICIs vs TKIs plus ICIs for Unresectable BCLC Stage C Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study |
Li-Nan Yin | Harbin Medical Univisity Cancer Hospital, China |
| 3 | 16:29-16:37 |
Safety of percutaneous transpulmonary microwave ablation for liver tumors under mechanical ventilation: a single-center retrospective study |
Yong-Hui Xia | The First Affiliated Hospital of China Medical University, China |
| 4 | 16:37-16:45 |
Needle angle display-assisted CT-guided trans-thoracic radiofrequency ablation for hepatic dome tumors |
Cheng-Shi Chen | Department of interventional radiology, the affiliated cancer hospital of Zhengzhou University&Henan Cancer Hospital, Zhengzhou University, China |
| 5 | 16:45-16:53 |
A Single-Center, Prospective, Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Epalrestat Combined With Hepatic Arterial Infusion Chemotherapy (HAIC), TKI and immunotherapy as First-Line Therapy in Patients With Unresectable Hepatocellular Carcinoma |
Tao Han | General Hospital of Shenyang Military Command, China |
| 6 | 16:53-17:05 |
Efficacy and Safety of HAIC Combined with Donafenib and Sintilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma: A Prospective Phase II Study (The DoHAICs Study) |
Wei Gao | Tianjin Medical University Cancer Institute & Hospital, China |
| 7 | 17:05-17:17 |
Panel Discussion |
A LL |
| NO. | Time | Presentation Topic | Speaker | Affiliation / Organization |
|---|---|---|---|---|
| 1 | 17:17-17:25 |
From Unresectable to R0 Resection: Successful Conversion Therapy with "Intervention + T+A" for Synchronous Liver and Gastric Cancers |
Yang Zhao | Hunan Cancer Hospital, China |
| 2 | 17:25-17:33 |
Case Report: Conversion Therapy Using "T+A" Combined with TACE for Intermediate-to-High Burden Unresectable Hepatocellular Carcinoma |
Jian Zhang | The Second Affiliated Hospital of Soochow University, China |
| 3 | 17:33-17:41 |
Trans-arterial Chemoembolization Combined with l Liver Venous Deprivation“Dual Conversion” versus TACE Alone in Hepatocellular Carcinoma with Insufficient Future Liver Remnant: A Real-World Retrospective Cohort Study |
Ying Yang | West China Hospital, Sichuan University, China |
| 4 | 17:41-17:49 |
Clinical Efficacy and Prognostic Factors of Atezolizumab Plus Bevacizumab Combined with On-demand Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma |
Jin-Peng Li | Shandong Cancer Hospital and Institute, China |
| 5 | 17:49-17:57 |
Efficacy and Survival Outcomes of Locoregional Therapy Combined with Targeted-Immune Triplet Therapy for Conversion Surgery in Initially Unresectable Hepatocellular Carcinoma |
Ning Ai | The Fourth Hospital of Hebei Medical University, China |
| 6 | 17:57-18:09 |
Panel Discussion |
A LL | |
| 7 | 18:09-18:14 |
Conclusion |
Hai-Peng Yu | Tianjin Medical University Cancer Institute & Hospital, China |
